1,574
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma

ORCID Icon, , , , , , , , , , , , , & show all
Pages 1323-1330 | Received 11 Jul 2021, Accepted 15 Dec 2021, Published online: 29 Dec 2021

References

  • Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–545.
  • Allen PB, Pro B. Therapy of peripheral T cell lymphoma: Focus on nodal subtypes. Curr Oncol Rep. 2020;22(5):44.
  • Horwitz S, O'Connor OA, Pro B, ECHELON-2 Study Group, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
  • Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des lymphomes de l’Adulte (GELA). Blood [Internet]. 1998;92:76–82.
  • Weisenburger DD, Savage KJ, Harris NL, for the International Peripheral T-cell Lymphoma Project, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood [Internet]. 2011;117(12):3402–3408.
  • Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood [Internet]. 2004;103(7):2474–2479.
  • Marchi E, O'Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management . CA Cancer J Clin. 2020;70(1):47–70.
  • Mantzorou M, Koutelidakis A, Theocharis S, et al. Clinical value of nutritional status in cancer: What is its impact and how it affects disease progression and prognosis? Nutr Cancer. 2017;69(8):1151–1176.
  • Ignacio de Ulíbarri J, González-Madroño A, de Villar NGP, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp [Internet]. 2005;20:38–45.
  • Kheirouri S, Alizadeh M. Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: a systematic review. Adv Nutr [Internet]. 2020;12(1):234–250.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood [Internet]. 2016;127(20):2375–2390.
  • International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive Non-Hodgkin’s lymphoma. N Engl J Med [Internet]. 1993;329:987–994.
  • Kanda Y. Investigation of the freely available easy-to-use software “ 'EZR' for medical statistics” . Bone Marrow Transplant. 2013;48(3):452–458.
  • Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.
  • Ureshino H, Kusaba K, Kidoguchi K, et al. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Ann Hematol. 2019;98(2):465–471.
  • Nagata A, Kanemasa Y, Sasaki Y, et al. Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B‐cell lymphoma. Hematol Oncol [Internet]. 2020;38(3):309–317.
  • Matsukawa T, Suto K, Kanaya M, et al.; North Japan Hematology Study Group (NJHSG). Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma. Ann Hematol. 2020;99(12):2859–2868.
  • Okamoto S, Ureshino H, Kidoguchi K, et al. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99(1):113–119.
  • Kamiya T, Ito C, Fujita Y, et al. The prognostic value of the controlling nutritional status score in patients with multiple myeloma. Leuk Lymphoma. 2020;61(8):1894–1900.
  • Sakurai A, Nakazato T. The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine. Leuk Lymphoma. 2020;61(12):2995–2997.
  • Hamaker ME, Oosterlaan F, van Huis LH, et al. Nutritional status and interventions for patients with cancer - A systematic review. J Geriatr Oncol. 2021;12(1):6–21.